A proposed rule published July 13, 2026 would materially reshape how the US FDA administers drug establishment registration for two growing segments of the pharmaceutical supply chain: companies pursuing decentralized, hub-and-spoke manufacturing models and the upstream foreign suppliers whose products ultimately reach US patients. The rule, developed under FDA's Framework for Regulatory Advanced Manufacturing Evaluation (FRAME) initiative, addresses a structural mismatch between existing registration regulations and the operational realities of advanced distributed manufacturing — and separately closes a compliance gap that has left a significant portion of the global API supply chain outside FDA's inspection planning framework. The proposal also marks FDA's transition from exploring distributed manufacturing through policy initiatives such as FRAME to embedding the concept directly into its core establishment registration regulations.
What Happened
FDA published the proposed amendments to 21 CFR Part 207 in the Federal Register on July 13, 2026. The proposal advances two distinct regulatory objectives: creating a tailored registration pathway for distributed manufacturing establishments (DMEs) and aligning drug listing requirements and foreign establishment registration rules with statutory changes made by the Preparing for and Responding to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act) of 2022. Public comments are due September 11, 2026.
What It Covers
A New Drug Establishment Registration Pathway for Distributed Manufacturers
Under current regulations, the term "establishment" is defined as "a place of business under one management at one general physical location" — a definition that effectively requires each physically separate manufacturing unit within a distributed operation to register independently. For a hub-and-spoke manufacturer with multiple dispersed units, this means duplicative registrations, separate fee obligations, and a fragmented administrative footprint that does not reflect how the operation actually functions.
The proposed rule would amend the definition of "establishment" to expressly include DMEs, and introduce three new defined terms: distributed manufacturing establishment, distributed manufacturing hub, and distributed manufacturing unit (DMU). A DME would be defined as a hub-and-spoke operation in which DMUs are equivalent in design and operation, manufacture the same drugs, and operate under the oversight of a single quality unit that has implemented a unified pharmaceutical quality system (UPQS) at the hub. The entire structure would register as a single establishment.
The framework includes tailored timelines for registration updates: additions or removals of DMUs would be handled as expedited updates rather than new registrations, with domestic DMU relocations requiring 30-day advance notice and international moves requiring 120 days — timelines FDA calibrates to the practical demands of scheduling foreign inspections, including visa processing and country clearances.
Eligibility for DME registration is not open-ended. A DME must have undergone preapproval inspection in connection with an approved marketing application — NDA, ANDA, BLA, or animal drug equivalent — that describes decentralized manufacturing for at least one drug in each profile class the DME manufactures. This requirement ensures FDA has had direct inspectional exposure to the UPQS before a streamlined registration structure is granted.
Foreign Drug Establishments and Drug Listing Requirements
The second component codifies in regulation what the PREVENT Pandemics Act already established in statute: that foreign establishments engaged in manufacturing drugs that are ultimately imported into the United States must register and list those drugs with FDA, regardless of whether the drug undergoes further processing at a separate foreign establishment before US entry.
Before the PREVENT Pandemics Act, a foreign API manufacturer that distributed exclusively to other foreign finished-product manufacturers was not required to register, even if those finished products were subsequently imported into the United States. FDA's own 2016 regulatory impact analysis acknowledged this gap. The proposed rule would eliminate any regulatory ambiguity by expressly extending registration and drug listing requirements to these upstream manufacturers.